Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Strumberg, Dirk; E. Scheulen, M.; Schultheis, Beate; Richly, Heike; Frost, Annette; Büchert, Martin; Christensen, O.; Jeffers, Michael; Heinig, Roland; Boix, Oliver; Mross, K.

doi:10.1038/bjc.2012.153

Public

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Published in British Journal of Cancer • May 1, 2012

Authors:

Dirk Strumberg

M. E. Scheulen

Beate Schultheis

Abstract

BACKGROUND: In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC). METHODS: Patients received oral regorafenib 60-220 mg daily (160 mg daily in th...

Subject

Regorafenib

Tolerability

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!